Acthar (Corticotropin) Patent Expiration, LOE Window & CMS Spending

Acthar (Corticotropin) by Mallinckrodt: Off-Patent Uncontested (0 AB Generics), 0 AB generics, $400.5M 2024 CMS Part D & Medicaid spend, and $35,187 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMallinckrodt
FDA Application & PathwayN007504 (NDA)
Exclusivity / Cliff HorizonOff-Patent Uncontested (0 AB Generics)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$400.5M
2024 Medicare Part D Spend$360.1M
2024 Medicaid Spend$40.4M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($35,187 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Mallinckrodt across sibling Meru public-data platforms.